CClinicalTrials.gg
RecruitingNCT07346586Updated Sep 29, 2026

Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery

An interventional study of Tamsulosin group and 24-Hour Removal Group in Urinary Catheters, Rectal Cancer and Urinary Retention, sponsored by The First Hospital of Jilin University. Recruiting at 2 sites in China. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by The First Hospital of Jilin University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
1,545
Allocation
Randomized
Sex
All
01

Study summary

This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer. Current clinical practice faces controversy regarding the optimal timing of catheter removal (24 hours vs. 48 hours) and lacks precise preventive measures for patients at high risk of postoperative acute urinary retention (AUR). To address these issues, this study is designed as a three-arm randomized controlled trial, directly comparing three management protocols: catheter removal at 24 hours postoperatively, catheter removal at 48 hours postoperatively, and urinary catheter removal within 24 hours combined with prophylactic tamsulosin. The primary endpoint is the rate of recatheterization within 7 days after the initial removal, with secondary endpoints comprehensively assessing urinary tract infections, voiding function, and postoperative complications. The ultimate goal is to provide high-quality evidence-based medical evidence to establish a precise and standardized clinical pathway for postoperative catheter management.

02

Conditions studied

  • Urinary Catheters
  • Rectal Cancer
  • Urinary Retention

Keywords

  • Urinary Retention
  • Rectal Cancer
  • Catheter
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients with a preoperative pathological confirmation of rectal malignant tumor.
  2. Preoperative colorectal CT or rectal MRI confirming that the lower edge of the tumor is located in the rectum within 10 cm from the anal verge (including rectal and anal canal lesions).
  3. Patients scheduled to undergo laparoscopic or robot-assisted radical total mesorectal excision (TME).
  4. Patients with a most recent preoperative clinical stage, including restaging after neoadjuvant therapy, of cT0 (clinical complete response [cCR]) to cT4 and cN0-N2 were eligible. For cT4 disease, tumor invasion was limited to the levator ani muscle or external anal sphincter.

Exclusion criteria

Exclusion Criteria:

  1. History of previous abdominal surgery involving the rectum/sigmoid colon/left colon, bladder resection or partial resection, prostate surgery (in males), or hysterectomy (in females).
  2. History of urethral trauma, intracranial surgery, spinal surgery, cerebral infarction with limb dysfunction, or Parkinson's disease.
  3. Inability to void urethrally preoperatively due to any reason (e.g., ureteral puncture, ureterostomy).
  4. Previously diagnosed overactive bladder syndrome, prior AUR or voiding dysfunction, or diabetic cystopathy.
  5. Preoperative assessment indicating potential need for combined resection of other pelvic organs during surgery, including the bladder, prostate, uterus and cervix, or vagina (excluding simple adnexectomy in females).
  6. Preoperative assessment indicating potential need for lateral pelvic lymph node dissection.
  7. Preoperative renal insufficiency (serum creatinine level >133 μmol/L).
  8. Patients undergoing emergency surgery.
  9. Male patients with preoperative benign prostatic hyperplasia requiring medication.
  10. Presence of indwelling ureteral stents, ureteral stenosis, or bilateral hydronephrosis.
  11. Severe lower urinary tract symptoms based on the preoperative International Prostate Symptom Score (IPSS).
  12. Previous use of an α1-adrenergic receptor blocker.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,545 participants (estimated)

Study arms

  • Experimental
    Tamsulosin Group

    Participants assigned to this arm underwent urinary catheter removal at 04:00 AM on postoperative day 1 and received prophylactic oral tamsulosin 0.4 mg once daily from one day before surgery through postoperative day 7.

    Behavioral: Tamsulosin group

  • Experimental
    24-Hour Removal Group

    Participants do not receive prophylactic tamsulosin before urinary catheter removal. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 1.Oral tamsulosin (0.4 mg once daily) was initiated if patients failed to void spontaneously within 6 hours after urinary catheter removal or developed lower urinary tract symptoms.

    Behavioral: 24-Hour Removal Group

  • Active comparator
    48-Hour Removal Group

    Participants do not receive prophylactic tamsulosin before urinary catheter removal. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 2.Oral tamsulosin (0.4 mg once daily) was initiated if patients failed to void spontaneously within 6 hours after urinary catheter removal or developed lower urinary tract symptoms.

    Behavioral: 48-Hour Removal Group

Interventions

  • BehavioralTamsulosin group

    Tamsulosin regimen: Tamsulosin 0.4 mg was administered orally once daily at 18:00 from the day before surgery to postoperative day 7. On the day of surgery, if the patient had not returned to the ward by 18:00, the dose was given after return to the ward and recovery from anesthesia. On postoperative day 1, if the patient had not voided within 6 hours after catheter removal or developed lower urinary tract symptoms, the daily dose was administered early and was not repeated at 18:00. Catheter removal: The urinary catheter was removed at 04:00 on postoperative day 1.

  • Behavioral24-Hour Removal Group

    Participants do not receive prophylactic tamsulosin. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 1.For patients who failed to void within 6 hours after catheter removal or developed lower urinary tract symptoms, oral tamsulosin 0.4 mg was administered, and micturition status was assessed after 4 hours of observation. Thereafter, oral tamsulosin 0.4 mg was given daily at 18:00 for 7 days following catheter removal.

  • Behavioral48-Hour Removal Group

    Participants do not receive prophylactic tamsulosin. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 2. For patients who failed to void within 6 hours after catheter removal or developed lower urinary tract symptoms, oral tamsulosin 0.4 mg was administered, and micturition status was assessed after 4 hours of observation. Thereafter, oral tamsulosin 0.4 mg was given daily at 18:00 for 7 days following catheter removal.

05

What researchers measure

Primary outcomes

  1. Rate of recatheterization within 7 days after the initial catheter removal

    If a patient had not urinated spontaneously by 10 h after catheter removal and had a bladder extending above the pubic symphysis on percussion, or was able to void but had lower urinary tract symptoms (LUTS), and these conditions persisted despite oral tamsulosin, bladder ultrasonography was performed to measure the post-void residual (PVR) urine volume. Recatheterization will be performed if: 1. The PVR volume is \>500 mL, or 300-500 mL with accompanying LUTS; 2. The PVR volume is 300-500 mL without LUTS or ≤300 mL. In these cases, patients are observed for an additional 2-4 h, and recatheterization is performed if no spontaneous voiding occurs or symptoms worsen.

    Time frame: Within 7 days after the initial catheter removal

Secondary outcomes

  1. Incidence of Urinary Tract Infection (UTI).

    Urinary Tract Infection is defined as the inflammatory response of the urinary tract epithelium to bacterial invasion. The diagnosis must simultaneously satisfy the following two criteria: 1) Urinalysis indicates that the urinary bacterial count exceeds the upper limit of the normal range, and 2) Urine culture is positive. Incidence of UTI is calculated as a ratio: UTI cases occurring after first catheter removal divided by the total number of enrolled participants.

    Time frame: Within 7 days after the initial catheter removal

  2. Time to First Successful Voiding after Catheter Removal

    The time to first void after catheter removal is defined as the period from the time of catheter removal to the time when the patient voids spontaneously, measured in hours.

    Time frame: Within 1 days after the initial catheter removal

  3. Recatheterization rate within 30 days after urinary catheter removal

    Recatheterization within 30 days was defined as reinsertion of a urinary catheter for any reason after initial catheter removal.

    Time frame: Within 30 days after the initial catheter removal

  4. The incidence of events triggering oral tamsulosin after catheter removal (24-Hour Removal Group and 48-Hour Removal Group) or triggering early oral tamsulosin administration (Tamsulosin Group).

    Tamsulosin administration is triggered by either of the following: (1) failure to void spontaneously within 6 hours after urinary catheter removal; or (2) the occurrence of lower urinary tract symptoms at any time, including a sensation of incomplete bladder emptying, urinary urgency, urinary frequency, intermittent urine flow, straining to void, bladder pain or distension, urgency urinary incontinence, or suspected overflow incontinence. For participants in Tamsulosin Group, if any of the above conditions occurs before the scheduled 18:00 dose, that day's dose is administered immediately, is not repeated at 18:00, and the event is recorded as a trigger for early oral tamsulosin.

    Time frame: Within 7 days after the initial catheter removal

  5. Incidence, types, and severity (graded by Clavien-Dindo classification) of postoperative complications within 30 days.

    The Clavien-Dindo classification includes, but is not limited to, intra-abdominal hemorrhage, gastrointestinal bleeding, anastomotic leakage, chyle leakage, surgical site infection (intra-abdominal infection and incisional infection), intestinal obstruction, postoperative diarrhea, pulmonary infection, urinary tract infection, cardiovascular accident, cerebrovascular accident, and thrombotic diseases.

    Time frame: within 30 days postoperatively

06

Study locations

1 of 2 sites recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
    Not yet recruiting
  • The First Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07346586
Lead sponsor
The First Hospital of Jilin University
Responsible party
Yuchen Guo, Ph.D. (Prof., The First Hospital of Jilin University) — Principal investigator
First posted
Jan 16, 2026
Start date
Mar 18, 2026
Primary completion
Nov 20, 2029 (estimated)
Completion
Dec 20, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Yuchen Guo Yuchen Guo
Contact
guoyuchen8688@jlu.edu.cn
+8613630598312

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion